- Home
- PBYI vs DOUG Comparison
PBYI vs DOUG Comparison
Compare PBYI & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- DOUG
- Stock Information
- Founded
- PBYI 2010
- DOUG 1911
- Country
- PBYI United States
- DOUG United States
- Employees
- PBYI N/A
- DOUG N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- DOUG Building operators
- Sector
- PBYI Health Care
- DOUG Real Estate
- Exchange
- PBYI Nasdaq
- DOUG Nasdaq
- Market Cap
- PBYI 263.4M
- DOUG 219.1M
- IPO Year
- PBYI N/A
- DOUG N/A
- Fundamental
- Price
- PBYI $4.95
- DOUG $2.52
- Analyst Decision
- PBYI Strong Buy
- DOUG
- Analyst Count
- PBYI 1
- DOUG 0
- Target Price
- PBYI $7.00
- DOUG N/A
- AVG Volume (30 Days)
- PBYI 418.9K
- DOUG 382.0K
- Earning Date
- PBYI 11-06-2025
- DOUG 11-04-2025
- Dividend Yield
- PBYI N/A
- DOUG N/A
- EPS Growth
- PBYI 434.29
- DOUG N/A
- EPS
- PBYI 0.97
- DOUG N/A
- Revenue
- PBYI $238,062,000.00
- DOUG $1,030,928,000.00
- Revenue This Year
- PBYI N/A
- DOUG $17.61
- Revenue Next Year
- PBYI N/A
- DOUG N/A
- P/E Ratio
- PBYI $5.08
- DOUG N/A
- Revenue Growth
- PBYI 8.63
- DOUG 6.67
- 52 Week Low
- PBYI $2.32
- DOUG $1.48
- 52 Week High
- PBYI $6.07
- DOUG $3.20
- Technical
- Relative Strength Index (RSI)
- PBYI 45.94
- DOUG 44.96
- Support Level
- PBYI $5.14
- DOUG $2.25
- Resistance Level
- PBYI $5.52
- DOUG $2.89
- Average True Range (ATR)
- PBYI 0.25
- DOUG 0.13
- MACD
- PBYI -0.06
- DOUG -0.01
- Stochastic Oscillator
- PBYI 17.82
- DOUG 42.19
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.